Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

°¢Ë¹Àû¿µÒý½øË«¿¹ÔÚÖйú»ñÅúÁÙ´²Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ

2023-07-23
|
»á¼ûÁ¿£º

¸±±¾_ÍøÕ¾ËõÂÔͼ__2023-07-23+23_21_31.jpeg

Ò½ÏßÒ©ÎÅ

1¡¢7ÔÂ23ÈÕ£¬£¬£¬£¬£¬CDE¹ÙÍø×îй«Ê¾£¬£¬£¬£¬£¬°¢Ë¹Àû¿µ£¨AstraZeneca£©É걨µÄ1ÀàÐÂÒ©AZD5863»ñµÃÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬Ä⿪·¢ÖÎÁÆÍíÆÚ»ò×ªÒÆÐÔʵÌåÁö¡£¡£¡£¡£AZD5863£¨HBM7022£©ÊÇÒ»¿îCLDN18.2 x CD3Ë«ÌØÒìÐÔ¿¹Ìå¡£¡£¡£¡£

2¡¢7ÔÂ21ÈÕ£¬£¬£¬£¬£¬°Ù¼ÃÉñÖÝÐû²¼£¬£¬£¬£¬£¬Å·ÖÞÒ©Æ·¹ÜÀí¾Ö£¨EMA£©ÈËÓÃҩƷίԱ»á£¨CHMP£©ÒÑÐû²¼ÆäÍÆ¼ö¿¹PD-1µ¥¿¹ÌæÀ×ÀûÖéµ¥¿¹»ñµÃÉÏÊÐÔÊÐíµÄÆð¾¢Òâ¼û£¬£¬£¬£¬£¬½¨ÒéÅú×¼ÌæÀ×ÀûÖéµ¥¿¹µ¥Ò©ÓÃÓÚÖÎÁƼÈÍù½ÓÊܹýº¬²¬»¯ÁƵIJ»¿ÉÇгý¡¢¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔʳ¹ÜÁÛ״ϸ°û°©£¨ESCC£©³ÉÈË»¼Õß¡£¡£¡£¡£

3¡¢7ÔÂ22ÈÕ£¬£¬£¬£¬£¬Verrica PharmaceuticalsÐû²¼£¬£¬£¬£¬£¬ÃÀ¹úFDAÅú×¼ÆäËù¿ª·¢µÄYcanth£¨cantharidin£¬£¬£¬£¬£¬°ßòúËØ£©ÍâÓÃÈÜÒºÓÃÓÚÖÎÁÆ2Ëê¼°ÒÔÉϳÉÈ˺ͶùͯѬȾÐÔÈíðࣨmolluscum contagiosum£©»¼Õß¡£¡£¡£¡£

4¡¢7ÔÂ20ÈÕ£¬£¬£¬£¬£¬ÑîÉ­ÖйúÐû²¼ÆìÏÂÁ¢ÒìÒ©Îï˹ÄÍÈ𣨸»ÂíËá±´´ïà­ßøÆ¬£¬£¬£¬£¬£¬Ó¢ÎÄÉÌÆ·Ãû£ºSIRTURO£¬£¬£¬£¬£¬Ó¢ÎÄͨÓÃÃû£ºbedaquiline Fumarate Tablets£©»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾ÖÅú×¼£¬£¬£¬£¬£¬×÷ΪÁªºÏÖÎÁƵÄÒ»²¿·Ö£¬£¬£¬£¬£¬ÓÃÓÚ12ËêÖÁ<18ËêÇÒÌåÖØ¡Ý30kgµÄÇàÉÙÄêÄͶàÒ©·Î½áºËÖÎÁÆ¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1¡¢À³Ã¢ÉúÎïÐû²¼ÓëÓÅÈüŵÉúÎïÇ©ÊðÖÜȫսÂÔÏàÖúЭÒ飬£¬£¬£¬£¬Ë«·½½«Ì½Ë÷ǰÕßµÄÃâÒß´úÐ»ÖØ±à³Ì¼¼Êõ£¨Meta 10£©ÔÚͨÓÃÐÍCAR-TÖеÄÓ¦ÓÃת»¯ÄÜÁ¦£¬£¬£¬£¬£¬ÅäºÏÑз¢¡°¼«µÍ¼ÁÁ¿¡±µÄ¡°ÏÖ»õÐÍ¡±ÑªÒºÁöCAR-Tϸ°ûÖÎÁƲúÆ·¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

¿ËÈÕ£¬£¬£¬£¬£¬Ò»Æª½ÒÏþÔÚ¹ú¼ÊÔÓÖ¾The LancetÉϵÄÑо¿±¨¸æÖУ¬£¬£¬£¬£¬À´×ÔÃÀ¹ú²¼À³¸ù¸¾Å®Ò½ÔºµÈ»ú¹¹µÄ¿ÆÑ§¼ÒÃÇͨ¹ýÑо¿¹ØÓÚеĸ߼ÁÁ¿¿Ú·þÈü¸ñÁÐͪÅ䷽ȡµÃÁËеķ¢Ã÷£¬£¬£¬£¬£¬ËûÃÇÌåÏÖ£¬£¬£¬£¬£¬Ïà±È×îµÍµÄ14mg¼ÁÁ¿¶øÑÔ£¬£¬£¬£¬£¬ÌìÌì¿Ú·þÒ»´Î25mgºÍ50ºÁ¿ËµÄÈû¸ñÁÐͪÔÚ½µµÍѪÌÇˮƽ²¢Ôö½ø¼õ·Ê·½Ãæ»òÐíЧ¹û¸üºÃ[1]¡£¡£¡£¡£

Vanita R Aroda,Prof Jens Aberle,Lars Bardtrum,et al. Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial, The Lancet (2023). DOI:10.1016/S0140-6736(23)01127-3

¹Ø×¢¡°ÃÀ¸ß÷Medicilon¡±¹«Öںţ¬£¬£¬£¬£¬¶©ÔÄÀ¸Ä¿»ñÈ¡ÌìÌìÒ½Ò©×ÊѶ-1.png

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿